The Academic Conference on Gynecological Pathology 2024 and Sino-American Oncopathology Diagnostic Forum, organized jointly by Xiangtan Medical Association, Xiangtan Anti-Cancer Association, Chinese Pathological Society, and co-sponsored by Xiangtan Health Commission and Hengyang Medical College of South China University, took place smoothly from April 25th to 28th, 2024. Renowned experts and scholars from home and abroad were invited to lecture on recent advances and diagnostic standards in the fields of gynecological pathology and breast pathology. Concurrently, training workshops on breast and female reproductive system diseases pathology, as well as clinical pathology discussions, were held.

At this grand event, SpaceGen unveiled its gynecologic tumor gene testing products. One side of the booth showcased SpaceGen's cutting-edge technology, innovative products, and corporate development.

During the exhibition, the SpaceGen exhibition team patiently and meticulously explained the products to customers, carefully listened to their needs, and showcased mature molecular pathology-related products to pathology colleagues nationwide, receiving high attention and recognition from attending experts, colleagues, and pathology teachers.

Introduction to some gynecological testing products

It is worth mentioning that a series of gynecological tumor gene testing products such as "Human Endometrial Cancer Molecular Classification Detection Kit", "Human ctHPV16/18 Quantitative Detection Kit", and "MLH1 Gene Methylation Detection Kit" provided by SpaceGen are scientifically designed, comprehensive in coverage, and meet the practical needs of clinical applications.

SpaceGen’s Human Endometrial Cancer Molecular Classification Detection Kit

This service is based on the patented RingCap® technology of SpaceGen, which can provide independent prognostic information for endometrial cancer, and provide reference for adjuvant treatment and conservative treatment. It includes MMR gene mutation and MSI status detection, which can suggest the efficacy of immune checkpoint inhibitors and screen for Lynch syndrome.

Test Content

This test uses high-throughput sequencing methods to cover 12 genes related to endometrial cancer molecular subtyping, such as POLE, TP53, MLH1, MSH2, PMS2, MSH6, and 34 MSI-related sites.

Testing Advantages

1. Scientific rigor: Molecular subtyping included in the NCCN guidelines;

2. Simple and fast: Independent patented RingCap® technology, library construction can be completed in just two steps;

3. High sensitivity: 5000X sequencing depth, sensitivity up to 1%;

4. Comprehensive testing: One-time testing of 12 genes related to endometrial cancer molecular subtyping and 34 MSI sites, wide coverage.

SpaceGen’s Human PAX1 Gene Methylation Detection Kit

Abnormal methylation levels of the PAX1 gene can reflect the pathological process from different stages of precancerous lesions to cervical cancer to a certain extent, which is closely related to the occurrence and progression of cervical cancer, and earlier than conventional liquid-based cytology (TCT) detection. Conducting PAX1 gene methylation detection combined with HPV detection and TCT detection can help increase the detection rate of cervical cancer.

Significance of Testing

1. HPV-positive or TCT-abnormal individuals can detect PAX1 methylation as an auxiliary means of cervical cancer screening;

2. As a preliminary screening diversion tool to reduce unnecessary colposcopy;

3. Increase the detection rate of cervical adenocarcinoma;

4. Disease monitoring, prognosis.

Applicable Population

1. Population for cervical cancer screening;

2. Patients with repeated cervical inflammation, repeated infections, or unexplained vaginal bleeding;

3. High-risk HPV-positive or non-16/18 high-risk HPV-positive patients;

4. Patients with TCT test results of ASC-US and above;

5. Patients undergoing disease monitoring or treatment for cervical lesions or cervical cancer.

At this annual meeting, SpaceGen not only showcased its own technical strength and product advantages but also conducted in-depth exchanges and cooperation with many industry experts, scholars, and colleagues. In the future, SpaceGen will continue to uphold the concept of "quality first, reputation first, management-based, service-oriented", continuously improve innovation capabilities, contribute to the development of the genetic sequencing industry, and make greater contributions to the clinical research field.